" class="no-js "lang="en-US"> AstraZeneca - Medtech Alert
Friday, March 01, 2024
AstraZeneca | Pharmtech Focus


About AstraZeneca


AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers.

We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do. We focus on three main therapy areas – Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory – and we are also selectively active in the areas of autoimmunity, neuroscience and infection.

To put ourselves in the best position to push the boundaries of science, we seek to leverage our combination of capabilities, which encompass both small molecules and biologics, and include immunotherapies and developing innovative delivery devices that can offer choice to patients. These are reinforced by a strong focus on personalised healthcare capabilities, which aim to match medicines only to those patients who will benefit from them. Our teams also work alongside the world’s leading academic and biotech research institutions to stimulate innovation and evaluate emerging technologies such as Modified RNA and CRISPR genome editing.

Related Story

Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases

June 9 2023

Quell Therapeutics, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions […]

LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate

May 15 2023

LaNova Medicines has announced it has entered into an exclusive license agreement with AstraZeneca, for […]

Eplontersen Halted ATTRv-PN Disease Progression and Improved Neuropathy Impairment and Quality of Life in Study

April 25 2023

Ionis Pharmaceuticals today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis’ eplontersen […]

Personalis Selected for Clinical Research by AstraZeneca After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

March 8 2023

Personalis, a leader in advanced genomics for precision oncology, today announced it will continue its […]

AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy

December 2 2022

AstraZeneca has announced an agreement to acquire Neogene Therapeutics, a global clinical-stage biotechnology company pioneering […]

Vaxzevria Approved in the EU as Third Dose Booster Against COVID-19

May 23 2022

AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the […]

AstraZeneca Signs Licence Agreement With RQ Biotechnology for Monoclonal Antibodies Against COVID-19

May 18 2022

AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a […]

BenevolentAI Achieves Third Milestone in Its AI-enabled Drug Discovery Collaboration With AstraZeneca

May 17 2022

BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug discovery company, today announces that AstraZeneca […]

RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies

May 17 2022

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology […]

LifeArc Co-founded Company RQ Bio Signs Licensing Agreement With AstraZeneca Worth Up to $157m Plus Royalties for Monoclonal Antibodies Against SARS-CoV-2

May 17 2022

LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has signed […]

Farxiga Met Primary Endpoint in DELIVER Phase III Trial, Reducing Risk of Cardiovascular Death or Worsening Heart Failure in Patients with Preserved Ejection Fraction

May 6 2022

High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically […]

Enhertu Approved in the US for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen

May 6 2022

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of […]

Huma and AstraZeneca Partner to Accelerate Innovation for Digital-First Patient Care

March 23 2022

Huma Therapeutics Limited, a global digital health technology company advancing digital-first care delivery and research […]

BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure

January 17 2022

BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration […]

Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development

January 11 2022

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision […]

Neurimmune Enters into a Collaboration and License Agreement with AstraZeneca to Develop and Commercialize NI006

January 7 2022

Neurimmune AG today announced that it has entered into an exclusive global collaboration and license […]

Vaxzevria Significantly Boosted Antibody Levels Against Omicron

December 23 2021

AstraZeneca’s Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a […]

Evusheld Long-acting Antibody Combination Retains Neutralising Activity Against Omicron Variant in Independent FDA Study

December 17 2021

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained  neutralising […]

Evusheld (Formerly AZD7442) Long-acting Antibody Combination Authorised for Emergency Use in the US for Pre-exposure Prophylaxis (Prevention) of COVID-19

December 9 2021

AstraZeneca‘s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the […]

AstraZeneca Unveils The Discovery Centre (DISC) in Cambridge

November 23 2021

AstraZeneca will today, in the presence of His Royal Highness The Prince of Wales, formally […]

Two Billion Doses of AstraZeneca’s COVID-19 Vaccine Supplied to Countries Across the World Less Than 12 Months After First Approval

November 16 2021

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine […]

SAGA Diagnostics Enters into Development Agreement with AstraZeneca

November 3 2021

SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology […]

AZD7442 Reduced Risk of Developing Severe COVID-19 or Death in TACKLE Phase III Outpatient Treatment Trial

October 11 2021

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca‘s AZD7442, a […]

Enhertu Granted Breakthrough Therapy Designation in US for Patients with HER2-positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-based Regimens

October 4 2021

The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in the […]

VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform

September 23 2021

VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) […]

AstraZeneca to Invest $360m in Advanced Manufacturing Facility in Ireland

September 21 2021

AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small […]

Imfinzi Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-stage Small Cell Lung Cancer

September 20 2021

Updated results from the CASPIAN Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice […]

Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics

September 2 2021

Thermo Fisher Scientific‘s clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing […]

Forxiga Approved in the EU for the Treatment of Chronic Kidney Disease in Patients With and Without Type-2 Diabetes

August 9 2021

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) […]

Vaxzevria is Highly Effective After One Dose Against Severe Disease or Hospitalisation Caused by Beta and Delta Variants of Concern

July 23 2021

Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of […]

Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma

July 8 2021

AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for […]

Oxford/AstraZeneca Alternative Now Available at Riverside Vaccination Centre

June 7 2021

Vaccination appointments are available for residents who are eligible at the Riverside Vaccination Centre in […]

‘We Can Treat It’: Mortality Rate of Rare Condition Linked to AstraZeneca Shot Plunges

June 7 2021

Doctors are now confident they can detect and treat the rare blood clotting syndrome associated […]

Calquence Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients with Chronic Lymphocytic Leukaemia and Sustained Patient Benefit at Four Years in the Front-line Setting

June 7 2021

Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior […]

Tagrisso Approved in the EU for the Adjuvant Treatment of Patients with Early-stage EGFR-mutated Lung Cancer

May 28 2021

AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult […]

Drug Discovery Gets Jolt of AI via NVIDIA Collaborations with AstraZeneca, U of Florida Health

May 21 2021

NVIDIA is collaborating with biopharmaceutical company AstraZeneca and the University of Florida’s academic health center, […]

Amgen Tezepelumab BLA Submitted to U.S. FDA

May 11 2021

Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to […]

UK Medicines Regulator Issues its First Authorisation Under Project Orbis

May 7 2021

A post-surgery treatment for lung cancer will be the first to receive an authorisation from […]

Imfinzi, Tremelimumab and Chemotherapy Demonstrated Significant Benefit Versus Chemotherapy Alone

May 7 2021

POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy […]

COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials

February 12 2021

The primary analysis of the Phase III clinical trials from the UK, Brazil and South […]